|1.||Gross, Coleman: 8 articles (10/2014 - 10/2009)|
|2.||Check, Jerome H: 8 articles (05/2014 - 08/2007)|
|3.||Goyeneche, Alicia A: 8 articles (01/2014 - 06/2007)|
|4.||Telleria, Carlos M: 8 articles (01/2014 - 06/2007)|
|5.||Belanoff, Joseph K: 7 articles (08/2015 - 08/2002)|
|6.||Lanari, Claudia: 7 articles (06/2015 - 01/2005)|
|7.||Hasselgren, Per-Olof: 7 articles (11/2012 - 02/2002)|
|8.||Lye, Stephen J: 7 articles (02/2012 - 07/2002)|
|9.||Fleseriu, Maria: 6 articles (04/2015 - 06/2012)|
|10.||Gemzell-Danielsson, Kristina: 6 articles (03/2013 - 09/2003)|
12/01/2003 - "Mid and late luteal phase administration of mifepristone at doses above 25 mg are highly effective in inducing endometrial bleeding in nonconceptional cycles. "
10/01/2000 - "In contrast, a mifepristone-prostaglandin combination has been shown to be a very effective treatment for occasional menstrual regulation, with vaginal bleeding induced in 98% of pregnant women, with menses delay of 11 days or less. "
05/01/1998 - "To describe the efficacy of mifepristone in the prevention of menstrual bleeding and ovulation, with similar observations in comparison groups. "
08/01/1995 - "Mifepristone when used alone caused poor efficacy with unacceptable vaginal bleeding. "
12/01/2000 - "Previous studies of medical abortion with mifepristone and a prostaglandin have reported percentages of subjects who experience cramping and/or bleeding relative to prostaglandin use. "
|2.||Leiomyoma (Uterine Fibroids)
02/01/2000 - "Mifepristone is a safe and effective drug for treating uterine leiomyoma. "
01/01/2013 - "The aim of this study was to evaluate the safety and improvement in quality of life using 10 mg and 5 mg daily doses of mifepristone for the treatment of uterine fibroids. "
06/01/2004 - "Published trials of mifepristone showed reduction in leiomyoma size and improvement in symptoms. "
07/01/2011 - "25 mg mifepristone produces reduction in leiomyoma size and uterine volume and produces symptomatic improvement in women with fibroids."
07/01/2011 - "To estimate the efficacy of daily administration of 25 mg mifepristone for the treatment of uterine leiomyoma. "
03/01/2003 - "In comparison with exclusive DDP treatment, combined treatment with RU486 and DDP resulted in significantly greater inhibition rates of the tumors (70.48% vs 21.55%, P < 0.01). "
12/01/2010 - "The present study evaluated the efficacy of mifepristone therapy in murine tumors restricted to males, i.e. "
02/01/2012 - "Tumors derived from undifferentiated caspase-1-ESCs were eliminated following 3 weeks of mifepristone treatment in vivo. "
08/01/2003 - "Early treatment with RU486 eradicated tumors; however, rechallenge of treated mice failed to demonstrate evidence of immunoprotection. "
03/01/2010 - "A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study."
11/01/2007 - "Treatment of Cushing's syndrome with mifepristone has been reported in a total of 18 patients, with daily doses ranging from 5 to 30 mg/kg. Case reports indicate that the mifepristone-induced receptor blockade may lead to significant clinical improvement in patients with Cushing's syndrome in whom surgery and inhibitors of adrenal steroidogenesis fail to control hypercortisolism. "
08/01/2001 - "This case illustrates the efficacy of high-dose long-term treatment with mifepristone in refractory Cushing's syndrome. "
10/01/2015 - "This post hoc analysis included 40 clinical responders and 50 participants who received a dose of mifepristone (safety population) in the 24-week phase 3 SEISMIC (Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing Syndrome) trial. "
10/01/2014 - "The Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing's Syndrome (SEISMIC) was a 24-week, open-label study of mifepristone, and its long-term extension (LTE) is a multicenter U.S. "
08/01/2013 - "We review the use of mifepristone, as published in the recent Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing's Syndrome (SEISMIC). "
01/01/2011 - "A total of 6 years after the report published in the Western world indicated that mifepristone may also be effective in treating endometriosis, the first paper on the same topic was published in China in 1997. "
09/01/1991 - "Daily administration of RU486 results in acyclic ovarian function and improvement in the subjective painful symptoms of endometriosis. "
01/01/2011 - "We retrieved 104 papers on clinical trials and trial-like studies conducted in China evaluating the use of mifepristone to treat endometriosis that were published in the last 11 years. "
01/01/2011 - "Use of mifepristone to treat endometriosis: a review of clinical trials and trial-like studies conducted in China."
03/18/2010 - "A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies."
|2.||Glucocorticoid Receptors (Glucocorticoid Receptor)
|3.||Progesterone Receptors (Progesterone Receptor)
|6.||Estrogen Receptor Modulators (Antiestrogen)
|7.||Gonadotropin-Releasing Hormone (GnRH)
|10.||Mifepristone (RU 486)
|2.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)